TNBCs have the strongest tumor immunogenicity among all breast cancer subtypes, and immunotherapies targeting PD-1 and PD-L1 have shown efficacy, 28 but therapies targeting cGas/STING are not yet practical and the efficacy of TNBCs as therapeutic targets is still unclear. This evidence concerns the gene CGAS and breast carcinoma.